Category: 3. Business

The Bank for International Settlements has reviewed the content of the FX Global Code and acknowledges that the Code represents a set of principles generally recognised as good practice in the wholesale foreign exchange (FX) market. The BIS confirms that it acts as a market participant as defined by the Code, and is committed to conducting its FX market activities in a manner consistent with the principles of the Code. To this end, the BIS has taken appropriate steps, based on the size and complexity of its activities, and the nature of its engagement in the FX market, to align its activities with the principles of the Code.

For 12 consecutive years, the Top Employers Institute has certified Samsung as the 2026 Top Employer of the Year. The global electronics giant has yet again been applauded for its consistent and exceptional performance in employee relations, workplace culture and human resources practices.

 

This Institute’s Certification Programme is a standout benchmark for HR excellence – recognising Samsung for its positive, inclusive and supportive environment that fosters teamwork, respect and a sense of belonging. Samsung’s certification was awarded after a rigorous, data-driven assessment of the organisation’s HR best practices across various domains, including people strategy, work environment, talent acquisition and employee well-being.

 

Some of the common factors that contributed to the distinction in this prestigious award included employee satisfaction, a clear indication of high levels of overall morale within Samsung coupled with engagement and job satisfaction – often measured through independent, employee surveys. This certification also provides organisations such as Samsung with insights to help them focus on any areas for improvement. 

 

Loren Naicker, People Group Head at Samsung South Africa said: “For us at Samsung, this recognition is quite significant – a testament of our continued dedication to our employees’ wellbeing, innovative work culture and strong career development opportunities. As a company, we would like to express our genuine gratitude to our people because this award is a direct result of their hard work and dedication.”

 

Samsung views its people as its greatest asset and strength. For this reason, the company supports its employees through its continued commitment to providing opportunities, fostering an inclusive culture and developing their full potential through various programmes. These professional development initiatives include some of Samsung’s most robust training programmes, clear paths for career advancement and ongoing investment in employees’ long-term growth and skills development.

 

Naicker adds: “This award is a strong external validation that our company is indeed a great place to work for. As Samsung, we pride ourselves on people-centric policies and initiatives that support a healthy equilibrium between professional and personal life. Importantly, this recognition continues to help in boosting our employees’ morale and enables us to attract the best talent that this country has to offer.”

A labour rights organisation claims it has found evidence of worker exploitation in a Chinese factory that makes the viral Labubu dolls.

China Labor Watch (CLW), a US-based non-governmental organisation, alleges that its investigation found that one of Pop Mart’s suppliers made employees work excessive overtime shifts, sign blank or incomplete contracts and did not give them paid leave.

The furry Labubu dolls have surged in popularity around the world in recent years and are best known for selling toys in “blind boxes”, which hide its content from buyers until it is opened.

Pop Mart told the BBC that it is investigating the claims.

The Beijing-based toy retailer said it appreciated the details from the review and that it will “firmly” require companies making its toys to correct their practices if the allegations are found to be true.

Pop Mart added that it conducts regular audits of its suppliers, including yearly independent third-party reviews carried out by internationally recognised inspectors.

CLW said in its report that it had carried out the in-depth probe into Labubu-maker, Shunjia Toys Co Ltd, in the southern Chinese province Guangdong.

The BBC has been unable to contact Shunjia Toys Co Ltd for comment.

CLW said its researchers conducted 51 in-person interviews with the factory’s employees to discuss matters of recruitment, contracts and their working conditions.

The factory is a “core manufacturing facility” of Pop Mart toys and employed more than 4,500 workers, according to CLW.

The organisation flagged labour issues at Shunjia Toys Co Ltd’s factory in Xinfeng County, including what it said were illegal overtime hours, unclear contract practices and a lack of safety training and protections.

No child labour was identified at the factory, but it had employed 16-year-old workers who were subject to the same working conditions as adults, without special care that is required under Chinese law, said CLW.

It urged Pop Mart to take “immediate action” to address the issues in its supply chain. The non-profit said the firm should compensate affected workers and ensure that its production line complies with Chinese labour laws and internationally recognised labour standards.

Such facilities, called original equipment manufacturers (OEM), make products according to pricing and production schedules set by the client.

“As a result, labour conditions in OEM facilities are closely shaped by brand sourcing practices,” said CLW.

Labubus – the fictional elf-like creatures with a row of jagged teeth have become hugely popular. The craze has sparked long queues in shops worldwide.

Celebrity endorsements from the likes of Kim Kardashian and Lisa from K-pop group Blackpink have helped Pop Mart to become a major toy retailer.

At CES 2026, Siemens’ keynote marked a new era of technology for industry and infrastructure, showcasing how customers and partners are harnessing artificial intelligence to transform their businesses. With AI-enabled technologies, deep domain expertise, and trusted partnerships, Siemens is converting this technological leap into measurable benefits for customers, partners, and society.

“Just as electricity once revolutionized the world, industry is shifting toward elements where AI powers products, factories, buildings, grids and transportation. Industrial AI is no longer a feature; it’s a force that will reshape the next century. Siemens is delivering AI-native capabilities, intelligence embedded end-to-end across design, engineering and operations, to help our customers anticipate issues, accelerate innovation and reduce cost,” said Roland Busch, President and CEO of Siemens AG. “From the most comprehensive digital twin and AI-powered hardware to copilots on the shop floor, we’re scaling intelligence across the physical world, so businesses realize speed, quality and efficiency all at once. This is how we scale a once-in-a generation technology shift into measurable outcomes.”

Siemens highlighted its long-standing partnership with NVIDIA at CES 2026: The companies are expanding their partnership to build the Industrial AI Operating System – helping customers revolutionize how they design, engineer, and operate physical systems. Siemens and NVIDIA will work together to build AI-accelerated industrial solutions across the full lifecycle of products and production, enabling faster innovation, continuous optimization, and more resilient, sustainable manufacturing. The companies also aim to build the world’s first fully AI-driven, adaptive manufacturing sites globally, starting in 2026 with the Siemens Electronics Factory in Erlangen, Germany, as the first blueprint.

To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. The companies have identified impact areas to make this vision a reality: AI-native EDA, AI-native Simulation, AI-driven adaptive manufacturing and supply chain, and AI-factories.

Siemens also announced that it will be integrating NVIDIA NIM and NVIDIA Nemotron open AI models into its electronic design automation (EDA) software offerings to advance generative and agentic workflows for semiconductor and PCB design. This will both maximize accuracy through domain specialization and significantly lower operational costs by enabling the most efficient model to handle and adapt to every specific need.

“Generative AI and accelerated computing have ignited a new industrial revolution, transforming digital twins from passive simulations into the active intelligence of the physical world,” said Jensen Huang, founder and CEO of NVIDIA. “Our partnership with Siemens fuses the world’s leading industrial software with NVIDIA’s full-stack AI platform to close the gap between ideas and reality — empowering industries to simulate complex systems in software, then seamlessly automate and operate them in the physical world.”

New Technology Connects Digital Twin with Real-Time, Real-World Data

Siemens’ primary product launch at CES 2026 is the Digital Twin Composer, available on the Siemens Xcelerator Marketplace mid-2026. This new technology brings together Siemens’ comprehensive digital twin, simulations built using NVIDIA Omniverse libraries, and real-time, real-world engineering data.

With the Digital Twin Composer, companies can create a virtual 3D model of any product, process, or plant; put it in a 3D scene of their choosing; then move back and forth through time, precisely visualizing the effects of everything from weather changes to engineering changes.

With Siemens’ software as the data backbone, the Digital Twin Composer builds Industrial Metaverse environments at scale, empowering organizations to apply industrial AI, simulation and real-time physical data to make decisions virtually, at speed and scale. Digital Twin Composer is part of Siemens Xcelerator, an industry proven portfolio of software used by companies worldwide to develop digital twins.

PepsiCo and Siemens are digitally transforming select U.S. manufacturing and warehouse facilities by converting them into high-fidelity 3D digital twins that simulate plant operations and the end-to-end supply chain to establish a performance baseline. Within weeks, teams optimized and validated new configurations to boost capacity and throughput, giving PepsiCo a unified, real-time view of operations with flexibility to integrate AI-driven capabilities over time.

Leveraging Siemens’ Digital Twin Composer, NVIDIA Omniverse libraries and computer vision, PepsiCo can now recreate every machine, conveyor, pallet route and operator path with physics level accuracy, enabling AI agents to simulate, test, and refine system changes – identifying up to 90 percent of potential issues before any physical modifications occur. This approach has already delivered a 20 percent increase in throughput on initial deployment and is driving faster design cycles, nearly 100 percent design validation and 10 to 15 percent reductions in capital expenditure (Capex) by uncovering hidden capacity and validating investments in a virtual environment.

New Industrial Copilots Streamline Manufacturing Operations

Siemens also spotlighted its partnership with Microsoft, in a conversation with Jay Parikh, executive vice president for CoreAI at Microsoft. Together, Siemens and Microsoft are bridging the worlds of IT and operations, with a collaboration centered on using AI to help organizations across industries improve productivity, resilience, and innovation. Among the highlights: cobuilding the award-winning industrial copilot.

Siemens also announced that it is expanding its set of AI-powered copilots across the industrial value chain. This will embed intelligence that extends from design and simulation to product lifecycle management, manufacturing, and operations.

Siemens will deploy nine new AI-powered copilots for its software offerings, this will include Teamcenter, Polarion, and Opcenter. These copilots, respectively, streamline product data navigation, reducing errors and accelerating time to market; automate compliance, helping to ensure faster regulatory approvals and lower risk; and transform manufacturing processes, driving cost savings and operational efficiency.

These copilots, along with the rest of Siemens’ expanding portfolio of industrial AI solutions, are available to companies of every size on the Siemens Xcelerator Marketplace.

AI-Driven Innovations in Life Sciences, Energy and Manufacturing

In life sciences, the acquisition of Dotmatics has enabled the integration of vast research data in AI solutions of Siemens, fueling drug discovery and development. With Dotmatics’ Luma platform, scientists can unify billions of data points generated across instruments and labs, creating a coherent foundation for AI-driven exploration. Combined with Siemens Simcenter simulation and digital twins, teams can rapidly test molecules, identify promising candidates, and virtually scale production to help life-changing therapies reach patients up to 50% faster and at a lower cost. In energy, Bob Mumgaard, CEO and co-founder of Commonwealth Fusion Systems, described how the company uses Siemens’ technologies as it leads the path to commercial fusion. Commonwealth Fusion Systems uses design software and a strong data backbone to help it accelerate the development of fusion machines that promise clean, limitless energy for generations to come.

In manufacturing, Siemens announced a collaboration to bring Industrial AI to Meta Ray-Ban AI Glasses. With hands-free, real-time audio guidance, safety insights, and feedback, shop floor workers will feel empowered to solve problems efficiently and confidently.

Technology to Transform the Everyday for Everyone

At the Siemens booth in the North Hall of the Las Vegas Convention Center, Siemens is showcasing how its technology transforms the everyday, for everyone. Featured solutions from Siemens and its customers that bring together design, simulation, automation, AI, and digital twin technology:

• PepsiCo is modernizing its global operations to meet evolving customer demands with greater speed and flexibility. With Siemens, the company is digitalizing manufacturing and warehousing processes, enabling faster innovation, more agile production, and smarter decision-making across its supply chain.
• Commonwealth Fusion Systems is pioneering the future of clean energy with commercial fusion. Faced with the challenges of building an entirely new industry, CFS partnered with Siemens to build a comprehensive data backbone and to accelerate the design and manufacturing of this clean, safe, and nearly limitless energy source.
• Haddy is reshaping manufacturing through AI-powered 3D printing and localized micro factories that deliver sustainable, high-quality products faster and closer to customers. Facing challenges around supply chain disruption, sustainability, and production agility, Haddy partnered with Siemens to streamline design, optimize operations, and scale efficiently.

Siemens is also revolutionizing how industrial automation is experienced with the launch of its eXplore tour mobile experience in North Hall. Housed in an 18-wheel vehicle, the eXplore tour delivers an interactive experience that highlights how Siemens technologies converge to drive continuous operational optimization and unlock new levels of efficiency. After CES, the eXplore tour will continue across the U.S. with stops including Realize LIVE in Detroit and Automate in Chicago.

For the first time, Siemens is hosting its autonomous vehicle experience located at West Hall 4352. The experience will feature Siemens’ new PAVE360 Automotive technology, a systemlevel digital twin, to accelerate the development of software-defined vehicles. It will demonstrate how this new technology works, with a real vehicle on site, operating autonomously in a completely virtual environment.

A recording of Siemens’ 2026 keynote is available via LinkedIn

About Siemens

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. In fiscal 2025, which ended on September 30, 2025, the Siemens Group generated revenue of €78.9 billion and net income of €10.4 billion. As of September 30, 2025, the company employed around 318,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at www.siemens.com.

Notes and forward-looking statements

This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning.

We may also make forward-looking statements in other reports, in prospectuses, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens’ management, of which many are beyond Siemens’ control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in disclosures, in particular in the chapter Report on expected developments and associated material opportunities and risks in the Combined Management Report of the Siemens Report.

Should one or more of these risks or uncertainties materialize, should decrees, decisions, assessments or requirements of regulatory or governmental authorities deviate from our expectations, should events of force majeure, such as pandemics, unrest or acts of war, occur or should underlying expectations including future events occur at a later date or not at all or assumptions prove incorrect, actual results, performance or achievements of Siemens may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures should not be viewed in isolation or as alternatives to measures of Siemens’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its Consolidated Financial Statements.

Other companies that report or describe similarly titled alternative performance measures may calculate them differently.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. All information is preliminary.

Ramadan brings visible shifts in how people spend their time, money and attention. Across the UAE, KSA and Türkiye, routines slow down, evenings get busier at home, and priorities lean into faith, family and giving.

For brands, these moments shape decisions across shopping, media, travel and charitable behaviour.

What this snapshot covers

This consumer insight snapshot highlights early Ramadan 2026 signals, including:

• Expected changes in daily routines
• Travel and at home behavior
• Brand choice and switching patterns
• Preferences around Ramadan advertising
• Changes in media habits during the month

And there is more available for purchase

This snapshot is a sneak peek. The full Ramadan 2026 dataset is already available.

It covers deeper insights across share of wallet, shopping behavior, travel plans, giving and media consumption, alongside audience and shopper profiles for the UAE, KSA and Türkiye. Get in touch with YouGov experts today for more insights.

HOUSTON, Jan. 14, 2026 /PRNewswire/ — Bristow Group Inc. (NYSE: VTOL) (the “Company” or “Bristow”) announced today the pricing of an upsized private offering of $500 million aggregate principal amount of 6.75% senior secured notes due 2033 (the “notes”) to eligible purchasers pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the offering is expected to occur on January 26, 2026 and is subject to the satisfaction of customary closing conditions.

The notes will mature on February 1, 2033 and will be issued at par. The notes will pay interest semi-annually and will be fully and unconditionally guaranteed, jointly and severally, on a senior secured basis, by the Company’s existing material, wholly owned domestic subsidiaries and certain existing material, foreign subsidiaries, as well as certain future subsidiaries. The notes will be secured by first-priority liens, subject to limited exceptions, on collateral that will consist of certain helicopters and related assets, together with substantially all of the other tangible and intangible property assets of the Company and the subsidiary guarantors (other than certain excluded assets), including approximately 119 pledged aircraft.

The Company will irrevocably deposit a portion of the net proceeds from the offering with the trustee under the indenture (the “2028 Notes Indenture”) governing its 6.875% Senior Secured Notes due 2028 (the “2028 Notes”) in an amount sufficient to redeem the 2028 Notes in full on March 1, 2026 and fund the payment of the principal, premium and interest to, but not including, such redemption date and all other sums payable under the 2028 Notes Indenture with respect to the 2028 Notes. As a result (and at the time) of such deposit, the 2028 Notes Indenture will be satisfied and discharged in accordance with its terms with respect to the 2028 Notes (the “Satisfaction and Discharge”). The Company intends to use any remaining net proceeds from the offering for general corporate purposes.

The notes are being offered and sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act, and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The offer and sale of the notes and the related subsidiary guarantees have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the notes or any other securities, nor shall there be any sale of the notes or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. Any offers of the notes shall be made in the United States only by means of a private offering circular pursuant to Rule 144A under the Securities Act, and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.

This press release does not constitute a notice of redemption with respect to the 2028 Notes.

About Bristow Group

Bristow Group Inc. is the leading global provider of innovative and sustainable vertical flight solutions. Bristow primarily provides aviation services to a broad base of offshore energy companies and government entities. Our aviation services include personnel transportation, search and rescue (“SAR”), medevac, fixed-wing transportation, unmanned systems and ad hoc helicopter services. Our business is comprised of three operating segments: Offshore Energy Services, Government Services and Other Services. Our energy customers charter our helicopters primarily to transport personnel to, from and between onshore bases and offshore production platforms, drilling rigs and other installations. Our government customers primarily outsource SAR activities whereby we operate specialized helicopters and provide highly trained personnel. Our other services include fixed-wing transportation services through a regional airline in Australia and dry-leasing aircraft to third-party operators in support of other industries and geographic markets.

Bristow currently has customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, Ireland, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the United Kingdom and the United States.

Forward-Looking Statements Disclosure

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements about our future business, strategy, operations, capabilities and results; financial projections; plans and objectives of our management; expected actions by us and by third parties, including our customers, competitors, vendors and regulators; and other matters. Some of the forward-looking statements can be identified by the use of words such as “believes,” “belief,” “forecasts,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “would,” “could,” “should” or other similar words; however, all statements in this press release, other than statements of historical fact or historical financial results, are forward-looking statements. Without limiting the generality of the foregoing, such forward-looking statements include statements regarding the use of proceeds from the offering and the Satisfaction and Discharge of the 2028 Notes. Our forward-looking statements reflect our views and assumptions on the date hereof regarding future events and operating performance. We believe that they are reasonable, but they involve significant known and unknown risks, uncertainties, assumptions and other factors, many of which may be beyond our control, that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks, uncertainties and factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, and in particular, the risks discussed in Part I, Item 1A, “Risk Factors” of such report and those discussed in other documents we file with the Securities and Exchange Commission. Accordingly, you should not put undue reliance on any forward-looking statements. There can be no assurance that the offering of the notes will be consummated on the terms described herein or at all.

All forward-looking statements in this press release are qualified by these cautionary statements and are only made as of the date thereof. The forward-looking statements in this press release should be evaluated together with the many uncertainties that affect our businesses, particularly those discussed in greater detail in Part I, Item 1A, “Risk Factors” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A, “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q. We disclaim any obligation or undertaking, other than as required by law, to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any change in events, conditions or circumstances on which the forward-looking statement is based, whether as a result of new information, future events or otherwise.

Investors
Bristow Group Inc.
Jennifer Whalen
InvestorRelations@bristowgroup.com

Media
Bristow Group Inc.
Adam Morgan
Adam.morgan@bristowgroup.com 

View original content:https://www.prnewswire.com/news-releases/bristow-group-announces-pricing-of-500-million-senior-secured-notes-in-an-upsized-private-offering-302661772.html

SOURCE Bristow Group

The roll out of the eID program is part of the Minns Government’s more than $1 billion biosecurity investment to protect and secure the agricultural sector.

Under the latest rebate program, eligible farmers and others can claim a 50 per cent rebate, up to a maximum of $1,500, on the purchase of a handheld eID reader. The rebate will be made available in early March 2026.

The latest round of funding is being offered to producers and livestock agents who may have missed out on the initial infrastructure rebate scheme in 2023.

Many producers and livestock agents are now recognising the practical value of this equipment, not just for meeting mandatory requirements such as property-to-property stock movements, but also for improving on-farm management through the collection of accurate individual animal data.

This information helps farmers make better-informed decisions, strengthening productivity, especially during challenging or variable seasonal conditions.

The equipment rebate follows a strong uptake of eID tags, with some 15.2 million eID tags purchased since November 2024, more than 1.79 million eIDs scanned in saleyards in 2025 and approximately 22.4 per cent of the sheep and goats coming through saleyards already equipped with an eID.

The NSW Government has committed $41 million for the implementation of mandatory electronic identification for sheep and goats in the state – the largest funding commitment of any state or territory.

Minister for Agriculture Tara Moriarty said:

“The equipment rebate is part of the Minns Labor Government’s ongoing financial support for primary producers in the transition to electronic IDs.

“Sheep and goat producers, along with livestock agents will benefit from this rebate, targeted specifically to reduce the cost of meeting mandatory eID requirements.

“This program ensures NSW producers will continue to lead the world in biosecurity safety and maintain their export premiums.

“We will continue working with producers, agents, saleyards and processors to implement eID in their operations.”

• AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients.^1,2
• Results from the SPACE trial found AJOVY significantly reduced monthly migraine days and monthly headache days versus placebo over a 12-week period in pediatric patients with episodic migraine.¹
• The U.S. Food and Drug Administration (FDA) approved AJOVY in August 2025 for the preventive treatment of episodic migraine in children and adolescents aged 6-17 years who weigh 45 kilograms (99 pounds) or more, building on its initial approval for the preventive treatment of migraine in adults.²

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the New England Journal of Medicine (NEJM) has published pivotal Phase 3 data on AJOVY, highlighting its efficacy and safety in children and adolescents with episodic migraine. The data from the SPACE study supported the FDA approval of AJOVY for the preventive treatment of episodic migraine in pediatric patients aged 6-17 years weighing 45 kilograms (99 pounds) or more, making it the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for preventive treatment of episodic migraine in pediatric patients and migraine in adults.^1,2

“With an estimated 1 in 10 children and adolescents in the U.S. living with migraine, the need for effective preventive options is critical as this condition can disrupt daily life for patients and families,” said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva.³ “The SPACE trial results published in the New England Journal of Medicine add to the growing body of evidence supporting AJOVY and build on its established use in adults. Teva is proud to be leading the charge and continuing to innovate for the migraine community.”

In the SPACE trial, AJOVY reduced monthly migraine days (MMD) by 2.5 days compared to 1.4 days with placebo (difference: 1.1 days; P = 0.02) and reduced monthly headache days (MHD) of at least moderate severity by 2.6 days versus 1.5 days (difference: 1.1 days; P = 0.02). A significantly higher proportion of participants achieved a ≥ 50% reduction in MMD (47.2%) with AJOVY compared to placebo (27.0%) (P = 0.002). No new safety signals were identified, and the safety profile remained consistent with that observed in adult studies.¹

The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous injections of fremanezumab (120 mg for those weighing < 45 kg; 225 mg for those weighing ≥ 45 kg) or matched placebo.¹

“Helping to prevent migraine attacks in children and adolescents is critical to supporting their healthy development and education, including missed school days, disability and overall social well-being,” said the study’s lead author, Andrew D. Hershey, M.D., Ph.D., and Endowed Chair and Director of Neurology at Cincinnati Children’s Hospital Medical Center. “The SPACE trial demonstrates that a CGRP-targeted preventive therapy like fremanezumab-vfrm (AJOVY) can significantly reduce the frequency of attacks of migraine in youth, giving physicians critical evidence to guide care for this underserved population.”

For more information on the SPACE study results published online in the New England Journal of Medicine, click here.

About Migraine

Migraine attacks cause disabling pain, nausea, vomiting and sensitivities to light and sound, resulting in serious effects on the ability to complete daily tasks.⁴ Migraine can cause significant disability in children and adolescents, leading to absence from school, impaired educational performance and missed social activities.⁵

About SPACE

SPACE is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety and tolerability of subcutaneous administration of fremanezumab versus placebo over a 12-week period for the preventive treatment of episodic migraine in 237 pediatric patients aged 6 to 17 years.

About AJOVY

AJOVY is indicated for preventive treatment of migraine in adults and episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. AJOVY can be administered either by a healthcare professional or at home by a patient 13 years of age or older or caregiver. No starting dose is required to begin treatment. For full prescribing information, visit https://www.ajovy.com/globalassets/ajovy/ajovy-pi.pdf

INDICATION AND USAGE

AJOVY is indicated for:

• the preventive treatment of migraine in adults, and
• the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.

IMPORTANT SAFETY INFORMATION

Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting.

Monitor patients treated with AJOVY for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of AJOVY is warranted.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AJOVY. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain.

AJOVY should be discontinued if signs or symptoms of Raynaud’s phenomenon develop. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions.

Please click here for full U.S. Prescribing Information for AJOVY (fremanezumab-vfrm) injection.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab-vfrm) injection for the prevention of episodic migraine in children and adolescents; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

1. Hershey, A. D., Szperka, C. L., Barbanti, P., Pozo‑Rosich, P., Bittigau, P., Barash, S., Bryson, J., Kessler, Y., Schwartz, Y. C., Campos, V. R., & Ning, X. (2026). Fremanezumab in Children and Adolescents with Episodic Migraine. New England Journal of Medicine.
2. AJOVY (fremanezumab-vfrm) injection, for subcutaneous use. Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc.
3. Al Khalili Y, Asuncion RMD, Chopra P. Migraine Headache in Childhood. [Updated 2023 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557813/
4. Jaimie D Steinmetz, Katrin Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Christopher J L Murray, Kanyin Liane Ong, Valery L Feigin, Theo Vos, and Tarun Dua on behalf of the GBD network. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. (in press).
5. Pediatric Migraine, An Update. Greene, Kaitlin. et al; Neurology clinics, Volume 37, Issue 4, 815-833. August 31, 2019. https://doi.org/10.1016/j.ncl.2019.07.009

Teva Media Inquiries:

TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquires

TevaIR@Tevapharm.com

Source: Teva Pharmaceutical Industries Ltd